Ayaan Parikh LinkedIn · Jul 2026
Founder post on the V2 diligence release, citing 150+ V1 customers and introducing proprietary decision data.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
AI-maximalist pharma platform that sources, evaluates, and packages overlooked drug assets with an agent stack; currently licenses modular products and runs pilots, with a long-term plan to acquire, develop, and sell assets.
Primary product
AI-native drug sourcing and diligence platform (CAS + CDD).
Founded
2025
Headquarters
1395 22nd St, San Francisco, CA 94107
Team size
1-10
Work style
Remote
Industry
Biotechnology Research
Sub-industry
AI drug discovery / pharma diligence platform
Offices
1395 22nd St, San Francisco, CA 94107 (HQ)
San Francisco, California, United States (second office location listed on LinkedIn)
Business model
Module licensing / enterprise pilots
Subscription SaaS
Per-report pricing
Long-term asset acquisition and development
Funding
People & investors
Work & culture
Early-stage, high-agency, research-heavy, and fast-moving; emphasizes human-in-the-loop validation, customer pilots, and a lean Stanford/YC-backed team.
Work style
Remote
Compensation
$90K-$200K salary and 0.50%-1.50% equity for listed roles; new grads welcome; remote in San Francisco/US.
Product & market
Pricing
Public self-serve pricing plus enterprise/module licensing and pilots: $199/mo for sourcing, $1,497 per report, and $2,997/mo for Convexia Pro.
Differentiators
- —Agentic end-to-end workflow spanning sourcing, diligence, clinical, and BD
- —50+ custom-tuned models and computational biology stack
- —Human-in-the-loop validation by PhDs/KOLs
- —Focus on overlooked assets and ex-US/preclinical opportunities
- —Modular productization with live pilots and licensing
- —Proprietary decision data for diligence
Technology
50+ custom drug-evaluation models
ESM-3
RFdiffusion
Boltz-2
AlphaFold
digital twin simulations
human-in-the-loop expert review
proprietary decision data
proprietary connectors
Stripe billing
Google SSO
Customers
Pilot customers in pharma, biotech, and investment groups
Small/mid pharma companies (targeted examples: Incyte, Nimbus, Roivant subcos)
Biotech VCs (targeted examples: Versant, Atlas, RA Capital)
Computational biotechs (targeted examples: Recursion, Insitro, Owkin)
150+ customers used V1 (public claim; unnamed)
Competitors
Partex
Formation Bio
BIOPTIC (Optic Inc.)
Bioneex
SourceScrub
Giotto Technologies
ArcaScience
Biorelate
Scale & contact
Estimated revenue
$170k-$220k estimated annual revenue (third-party estimates vary)
Estimated monthly visits
4.8K
Traffic estimate as of Jul 2026
Latest news
Convexia LinkedIn · Jan 2026
Company post adding Milind Kamkolkar and Dr. David Tierney to the team/advisor circle with deep pharma, data, and FDA-exit experience.
Ayaan Parikh LinkedIn · Jan 2026
Founder post claiming benchmark gains for sourcing, including more preclinical, Chinese, and shelved assets than legacy tools and frontier agents.
American Bazaar · Jul 2025
Independent launch coverage describing the product, agent stack, founders, and early market positioning.
Convexia LinkedIn · Jul 2025
Launch post announcing Convexia’s YC S25 debut, its AI-maximalist pharma positioning, and early customer pilots.
Jobs and careers at Convexia
0 jobs at Convexia
No open positions
Check back later for new openings